ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

LABS Life Science Reit Plc

38.50
0.30 (0.79%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Life Science Reit Plc LSE:LABS London Ordinary Share GB00BP5X4Q29 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.30 0.79% 38.50 38.00 38.50 38.50 38.50 38.50 488,107 16:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Real Estate Investment Trust 19.94M -21.71M -0.0620 -6.21 133.7M

Life Science REIT PLC Purchase of Ordinary Shares by Investment Adviser

15/11/2024 7:00am

RNS Regulatory News


RNS Number : 3376M
Life Science REIT PLC
15 November 2024
 

15 November 2024

LEI 213800RG7JNX7K8F7525

A green sign with white text Description automatically generated with medium confidence

Life Science REIT plc

("Life Science REIT" or the "Company")

 

Purchase of Ordinary Shares by Investment Adviser

 

Ironstone Asset Management acquires a further 532,252 ordinary shares in Life Science REIT plc

 

The Board of Life Science REIT (LSE: LABS), the real estate investment trust focused on UK life science properties, announces that, in accordance with the terms of the Investment Advisory Agreement ("IAA") between the Company and Ironstone Asset Management Limited, (the "Investment Adviser"), it has been notified that on 13 November 2024, the Investment Adviser has acquired 532,252 ordinary shares in the share capital of the company ("Ordinary Shares") at a weighted average price of 42.51 pence per share for a total cost of £227,439.34.

 

The Ordinary Shares have been purchased pursuant to the IAA, details of which were disclosed in the prospectus published by the Company on 14 November 2022.

 

Following the purchase, the Investment Adviser has an interest in 1.6 million Ordinary Shares, representing 0.46% of the Company's issued Ordinary Shares.

 

Along with this Investment Adviser purchase, Ironstone Asset Management Limited individuals also own shares in the Company, taking the total share ownership of the Investment Adviser and its principals to 5.1 million.

 

Enquiries:

Ironstone Asset Management - Investment Adviser

 +44 20 3011 2160

Simon Farnsworth, Managing Director

Simon.farnsworth@ironstoneam.com



Joanna Waddingham, Head of Investor Relations and Corporate Affairs



Joanna.Waddingham@ironstoneam.com





Link Company Matters Limited - Company Secretary


labs_cosec@linkgroup.co.uk




Panmure Liberum Limited - Joint Corporate Broker

+44 20 3100 2000

Alex Collins / Tom Scrivens





Jefferies International Limited - Joint Corporate Broker

+44 20 7029 8000

Tom Yeadon / Oliver Nott 

 


G10 Capital Limited - AIFM

+44 20 7397 5450

Maria Baldwin



 

FTI Consulting - Financial PR

 

+44 20 3727 1000

Dido Laurimore / Richard Gotla / Oliver Parsons



LifeScienceReit@fticonsulting.com



 

Notes to editors

Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.

 

Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is underpinned by strong structural drivers, including an ageing population and a supportive regulatory environment as well as the growing interdependence with technology, which is expanding the life science spectrum, driving strong demand for laboratory space.

 

The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.

 

The Company's investment policy is focused on capital growth whilst also providing a growing level of income.

 

Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.

Further information is available at https://lifesciencereit.co.uk. To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIBDBCDBDGSS

1 Year Life Science Reit Chart

1 Year Life Science Reit Chart

1 Month Life Science Reit Chart

1 Month Life Science Reit Chart